Rishi Desai

Rishi Desai

Auto-generated profile, based on publicly available information

Rishi Desai

Centers for Disease Control and Prevention, Atlanta, GA 30333, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RDRishi Desai
Rishi Desai
CHChristal D. Hembree
Christal D. Hembree
AHAndreas Handel
Andreas Handel
JMJonathan E. Matthews
Jonathan E. Matthews
BDBenjamin W. Dickey
Benjamin W. Dickey
BLBenjamin Lopman
Benjamin Lopman
Background. Noroviruses (NoVs) are the most common cause of epidemic gastroenteritis; however, the relative impacts of individual factors underlying severe illness are poorly understood. This report reviews published NoV outbreak reports to quantify hospitalization and mortality rates and assess their relationship with outbreak setting, transmission route, and strain. Methods. Using a string of terms related to “norovirus” and “outbreak,” we 2435 nonduplicate articles identified in PubMed, EMBASE, and Web of Knowledge published between January 1993 and June 2011. Inclusion criteria included outbreaks with a minimum of 2 ill persons with a common exposure and at least 1 reverse-transcription polymerase chain reaction–confirmed case of NoV disease. Univariate analyses were performed, and multivariable models were fitted to estimate the independent effect of each factor. Results. We analyzed 843 NoV outbreaks reported in 233 published articles from 45 countries. Based upon 71 724 illnesses, 501 hospitalizations, and 45 deaths, overall hospitalization and mortality rates were 0.54% and 0.06%, respectively. In multivariate analysis, genogroup 2 genotype 4 (GII.4) NoV strains were associated with higher hospitalization (incidence rate ratio [IRR], 9.4; 95% confidence interval [CI], 6.1–14.4; P < .001) and mortality rates (IRR, 3.1; 95% CI, 1.3–7.6; P = .01). Deaths were much more likely to occur in outbreaks occurring in healthcare facilities (IRR, 60; 95% CI, 6–109; P = .01). Conclusions. Our review suggests that hospitalizations and deaths were more likely in outbreaks associated with GII.4 viruses, independent of other factors, and underscores the importance of developing vaccines against GII.4 viruses to prevent severe disease outcomes.

1 January 2013 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
RDRishi Desai
Rishi Desai
MCMargaret M. Cortese
Margaret M. Cortese
MMMartin I. Meltzer
Martin I. Meltzer
MSManjunath Mb Bs Shankar
Manjunath Mb Bs Shankar
JTJacqueline E. Tate
Jacqueline E. Tate
UPUmesh D. Mb Bs Parashar
Umesh D. Mb Bs Parashar
Background: International data show a low-level increased risk of intussusception associated with rotavirus vaccination. Although US data have not documented a risk, we assumed a risk similar to international settings and compared potential vaccine-associated intussusception cases with benefits of prevention of rotavirus gastroenteritis by a fully implemented US rotavirus vaccine program. Methods: To calculate excess intussusception cases, we used national data on vaccine coverage and baseline intussusception rates, and assumed a vaccine-associated intussusception relative risk of 5.3 (95% confidence interval [CI]: 3.0–9.3) in the first week after the first vaccine dose, the risk seen in international settings. We used postlicensure vaccine effectiveness data to calculate rotavirus disease burden averted. Results: For a US birth cohort of 4.3 million infants, vaccine-associated intussusception could cause an excess 0.2 (range: 0.1–0.3) deaths, 45 (range: 21–86) hospitalizations and 13 (range: 6–25) cases managed in short-stay or emergency department settings. Vaccination would avert 14 (95% CI: 10–19) rotavirus-associated deaths, 53,444 (95% CI: 37,622–72,882) hospitalizations and 169,949 (95% CI: 118,161–238,630) emergency department visits. Summary benefit–risk ratios for death and hospitalization are 71:1 and 1093:1, respectively. Conclusions: The burden of severe rotavirus disease averted due to vaccination compared with the vaccine-associated intussusception events offers a side-by-side analysis of the benefits and potential risks. If an intussusception risk similar to that seen internationally exists in the United States, it is substantially exceeded by the benefits of rotavirus disease burden averted by vaccination.

27 April 2012 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
RDRishi Desai
Rishi Desai
ACAaron T. Curns
Aaron T. Curns
CSClaudia A. Steiner
Claudia A. Steiner
JTJacqueline E. Tate
Jacqueline E. Tate
MPManish M. Patel
Manish M. Patel
UPUmesh D. Parashar
Umesh D. Parashar
Rotavirus vaccine was recommended for US infants in 2006. We estimated baseline prevaccine burden and monitored postvaccine trends in gastroenteritis-coded and rotavirus-coded hospitalizations among US children. We analyzed data from the State Inpatient Databases (SID) for 29-44 US states over a 10-year period (2000-2009) to calculate gastroenteritis and rotavirus-coded hospitalization rates by age group, sex, and region, among children <5 years of age. By extrapolating observed pre- and postvaccine gastroenteritis hospitalization rates to the US population <5 years and based on the 2009 cost of a diarrhea hospitalization, we estimated national reductions in diarrhea hospitalizations and associated treatment costs. The prevaccine (2000-2006) annual average gastroenteritis-coded hospitalization rate among children <5 years of age was 74 per 10,000 (annual range, 71-82 per 10,000), and declined to 51 and 50 per 10,000 in 2008 and 2009, respectively (P < .001). The prevaccine (2000-2006) annual average rotavirus-coded hospitalization rate among children <5 years of age was 15 per 10,000 (annual range, 13-18 per 10,000), and declined to 5 and 6 per 10,000 in 2008 and 2009, respectively (P < .001). The decreases in rotavirus-coded hospitalization rates in 2008 and 2009 compared with rates in prevaccine years were observed among all age groups and US regions. Nationally, during 2008 and 2009 combined, we estimated a reduction of approximately 77,000 diarrhea hospitalizations and approximately $242 million in hospital costs. Since implementation of the US rotavirus vaccination program, a marked reduction in diarrhea hospitalizations and related hospital charges has occurred among US children.

1 December 2011 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
RDRishi Desai
Rishi Desai
LOLucia Helena de Oliveira
Lucia Helena de Oliveira
UPUmesh D Parashar
Umesh D Parashar
BLBenjamin Lopman
Benjamin Lopman
JTJacqueline E Tate
Jacqueline E Tate
MPManish M Patel
Manish M Patel
Countries in Latin America were among the first to implement routine vaccination against species A rotavirus (RVA). We evaluate data from Latin America on reductions in gastroenteritis and RVA disease burden following the introduction of RVA vaccine. Published literature was reviewed to identify case-control studies of vaccine effectiveness and population-based studies examining longitudinal trends of diarrhoeal disease reduction after RVA vaccine introduction in Latin American countries. RVA vaccine effectiveness and impact on gastroenteritis mortality and hospitalization rates and RVA hospitalization rates are described. Among middle-income Latin American countries with published data (Mexico, Brazil, El Salvador and Panama), RVA vaccine contributed to a gastroenteritis-associated mortality reduction of 22-41%, a gastroenteritis-associated hospitalization reduction of 17-51% and a RVA hospitalization reduction of 59-81% among children younger than five years of age. In Brazil and El Salvador, case-control studies demonstrated that a full RVA vaccination schedule was 76-85% effective against RVA hospitalization; a lower effectiveness of 46% was seen in Nicaragua, the only low-income country with available data. A growing body of literature offers convincing evidence of "real world" vaccine program successes in Latin American settings, which may be expanded as more countries in the region include RVA vaccine in their immunization programs.

19 June 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RDRishi Desai
Rishi Desai
AHAron J. Hall
Aron J. Hall
BLBenjamin A. Lopman
Benjamin A. Lopman
YSYair Shimshoni
Yair Shimshoni
MRMarcus Rennick
Marcus Rennick
UPUmesh D. Parashar
Umesh D. Parashar
Google Internet query share (IQS) data for gastroenteritis-related search terms correlated strongly with contemporaneous national (R2 = 0.70) and regional (R2 = 0.74) norovirussurveillance data in the United States. IQS data may facilitate rapid identification of norovirus season onset, elevated peak activity, and potential emergence of novel strains.

19 March 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RDRishi Desai
Rishi Desai
UPUmesh D. Parashar
Umesh D. Parashar
BLBenjamin Lopman
Benjamin Lopman
LOLucia Helena de Oliveira
Lucia Helena de Oliveira
ACAndrew D. Clark
Andrew D. Clark
MPManish M. Patel
Manish M. Patel
Background. With the recent postlicensure identification of an increased risk of intussusception with rotavirus vaccine, the 14 Latin American countries currently using rotavirus vaccine must now weigh the health benefits versus risks to assess whether to continue vaccination. To inform policy considerations, we estimated excess intussusception cases and mortality potentially caused by rotavirus vaccine for each of the 14 countries and compared these estimates to hospitalizations and deaths expected to be averted through vaccination. Methods. We used regional rotavirus disease burden and rotavirus vaccine efficacy data, global natural intussusception and regional rotavirus vaccine-related risk estimates, and country-specific diphtheria, tetanus, and pertussus vaccination coverage rates to estimate rotavirus vaccine coverage rates. We performed a probabilistic sensitivity analysis to account for uncertainty in these parameters. Results. For an aggregate hypothetical birth cohort of 9.5 million infants in these 14 countries, rotavirus vaccine would annually prevent 144 746 (90% confidence interval [CI], 128 821–156 707) hospitalizations and 4124 deaths (90% CI, 3740–4239) due to rotavirus in their first 5 years of life but could cause an additional 172 hospitalizations (90% CI, 126–293) and 10 deaths (90% CI, 6–17) due to intussusception, yielding benefit-risk ratios for hospitalization and death of 841:1 (90% CI, 479:1 to 1142:1) and 395:1 (90% CI, 207:1 to 526:1), respectively. In an uncertainty analysis using 10 000 simulations of our probabilistic parameters, in comparing rotavirus disease averted to intussusception events caused, the hospitalization ratio was never below 100:1, and our death ratio fell below 100:1 only once. Conclusions. The health benefits of vaccination far outweigh the short-term risks and support continued rotavirus vaccination in Latin America.